The Colored Iris Implants

The development and utilization of prosthetic iris implants represent a significant advancement in ophthalmic surgery, addressing a range of conditions from congenital iris deficiencies to traumatic injuries and functional abnormalities. Since the inception of this technology with the first prosthetic iris implantation in 1956, there has been continuous evolution and innovation leading to the development of various models designed for both functional and cosmetic purposes. However, the author outlines significant concerns regarding the use of cosmetic iris implants, emphasizing the reluctance of regulatory approval by key authorities such as the CE (Conformité Européenne) in Europe and the Food and Drug Administration (FDA) in the United States. However, in 2018, FDA finally approved the use of iris implants for treatment of iris defects, and in 2022, FDA-sanctioned, multicenter, prospective, unmasked, nonrandomized, interventional study demonstrated the safety and efficacy of the CustomFlex Artificial Iris for the treatment of partial or complete iris defects. The strong discouragement against their use for cosmetic purposes is based on the array of serious complications that can arise postoperatively, which are detailed extensively. These complications include but are not limited to uveitis (inflammation of the uvea), hyphema (blood in the anterior chamber of the eye), glaucoma (increased pressure in the eye that can lead to vision loss), cataract formation, corneal endothelial damage (which affects the inner most layer of the cornea), and severe vision loss.